Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Somatotropin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    106 result(s) found for: Somatotropin. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2004-002849-12 Sponsor Protocol Number: CSOM230B2201E1 Start Date*: 2005-01-12
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: Extension to a multicenter, randomized, crossover, open label, dose finding study to compare the safety, efficacy and PK/PD relationship of multiple doses of SOM230 (200, 400 and 600 µg b.i.d.) and...
    Medical condition: Acromegaly is a rare, serious condition characterized by chronic hypersecretion of GH (growth hormone) caused in over 95% of patients by a GH-secreting pituitary adenoma. Clinical manifestations ar...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10000599 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-005313-39 Sponsor Protocol Number: LAN-HD-ACRO Start Date*: 2013-05-17
    Sponsor Name:AZIENDA OSPEDALIERA Spedali Civili di Brescia
    Full Title: Scheme of treatment with high-dose lanreotide in acromegalic patients poorly responsive to treatment with standard doses."
    Medical condition: acromegaly
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003444-53 Sponsor Protocol Number: CSMS995BIT12 Start Date*: 2005-10-11
    Sponsor Name:NOVARTIS FARMA
    Full Title: A randomised, open label, multicenter study comparing the efficacy and safety of medical treatment with Sandostatin LAR 30 mg administered every 21 days for 6 months with that of Sandostatin LAR 60...
    Medical condition: Treatment of acromegalic patients partially responsive to somatostatin analogues
    Disease: Version SOC Term Classification Code Term Level
    6.1 10000599 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000500-83 Sponsor Protocol Number: 2-55-52060-002 Start Date*: 2008-07-15
    Sponsor Name:Ipsen Pharma
    Full Title: A phase II exploratory, ascending dose, multicentre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability, of BIM23A760 in acromegalic patients.
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) BE (Completed) IT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2007-005568-28 Sponsor Protocol Number: 2319/2007 Start Date*: 2007-10-11
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Safety study of rosiglitazone in patients with acromegaly and assessment of biochemical parameters of disease's activity.
    Medical condition: Acromegaly due to GH-secreting hypophysial adenoma, persistent after surgical adenomectomy, external radiotherapy or medical therapy with analogous of somatostatin.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003741-33 Sponsor Protocol Number: NRA6290020 Start Date*: 2007-12-17
    Sponsor Name:Barts and the London NHS Trust
    Full Title: A Study To Determine The Optimum Serum IGF-I Range In Patients With Acromegaly Treated With Pegvisomant
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004386-24 Sponsor Protocol Number: PEGACRO Start Date*: 2015-12-04
    Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Effect of GH receptor antagonist on insulin resistance associated with acromegaly
    Medical condition: acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003100-39 Sponsor Protocol Number: NSGA Start Date*: 2013-11-28
    Sponsor Name:Dutch Growth Research Foundation
    Full Title: Standardized versus individualized growth hormone treatment of short children born small for gestational age: Effects on short-term and longterm efficacy, long-term psychosocial development, gluc...
    Medical condition: Children who are born small for gestational age, defined as a birth length and/or birth weight < -2 SD score, who fail to show catch-up growth (short stature).
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004848 10018747 Growth hormone LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001313-14 Sponsor Protocol Number: 2007-189-2 Start Date*: 2012-10-17
    Sponsor Name:Dutch growth research foundation
    Full Title: Young adult Prader-Willi Study Effects of Growth Hormone after final height: A clinical care study to the optimal dosage of growth hormone in young adults with PWS.
    Medical condition: Prader Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10041331 Somatotrophin LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001364-72 Sponsor Protocol Number: EP00-402 Start Date*: 2008-01-04
    Sponsor Name:Sandoz GmbH
    Full Title: Long-term safety follow-up after growth hormone treatment (rhGH) of short children born Small for Gestational Age (SGA)
    Medical condition: Growth disturbance (current height standard deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children born small for gestational age (SGA), with a birth weight and/or length be...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004848 10018747 Growth hormone LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Completed) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005838-37 Sponsor Protocol Number: A-38-52030-214 Start Date*: 2008-05-15
    Sponsor Name:Beaufour Ipsen Pharma
    Full Title: A PROSPECTIVE, INTERNATIONAL, MULTI-CENTRIC, OPEN-LABEL STUDY TO ASSESS THE EFFICACY OF AN EXTENDED INJECTION INTERVAL SCHEDULE OF LANREOTIDE AUTOGEL 120 MG IN ACROMEGALIC SUBJECTS WHO ARE BIOCHEMI...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) DK (Completed) NL (Completed) FI (Completed) LV (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005431-70 Sponsor Protocol Number: CRN00808-09 Start Date*: 2022-03-04
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) AT (Completed) DE (Completed) HU (Ongoing) PL (Ongoing) BG (Ongoing) ES (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001292-51 Sponsor Protocol Number: CH-ACM-01-FU Start Date*: 2015-06-30
    Sponsor Name:Chiasma, Inc.
    Full Title: Follow-Up Study in Patients with Acromegaly Previously Participating in Chiasma Study CH-ACM-01
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SI (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005852-42 Sponsor Protocol Number: CSMS995BIC03 Start Date*: 2007-04-20
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open-label, two-step, multicenter European study to evaluate the efficacy and safety of Sandostatin LAR at High Dose or in combination either with GH-receptor antagonist or dopamine-agonist i...
    Medical condition: acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003327-23 Sponsor Protocol Number: IP107-001 Start Date*: 2008-10-29
    Sponsor Name:Endo Pharmaceuticals Solutions Inc
    Full Title: PHASE III, OPEN-LABEL, MULTICENTER INTERNATIONAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN OCTREOTIDE IMPLANT VERSUS SANDOSTATIN LAR® DEPOT IN PATIENTS WITH ACROMEGALY
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) DE (Completed) ES (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-004320-21 Sponsor Protocol Number: C2L-OCT-01 PR-302 Start Date*: 2007-10-29
    Sponsor Name:Ambrilia Biopharma Inc.
    Full Title: OPEN LABEL EXTENSION STUDY EVALUATING THE SAFETY AND BIOLOGICAL ACTIVITY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, ADMINISTERED INTRA MUSCULARLY EVERY 6 WEEKS IN ...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010787-42 Sponsor Protocol Number: 2-55-52060-003 Start Date*: 2009-09-02
    Sponsor Name:Ipsen Pharma
    Full Title: PHASE II, OPEN, RANDOMISED, PARALLEL GROUP, NONCOMPARATIVE MULTICENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPEATED SUBCUTANEOUS (S.C.) ADMINISTRATION OF DIFFERENT DOSES OF BIM 23A760 IN ACR...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) GB (Prematurely Ended) LV (Prematurely Ended) DE (Completed) FR (Completed) LT (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001972-36 Sponsor Protocol Number: CSOM230C2305 Start Date*: 2007-11-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, blinded study to assess the safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly.
    Medical condition: Acromegaly is characterized by chronic hypersecretion of growth hormone (GH), clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular diseas...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) BE (Completed) GB (Completed) GR (Completed) IT (Completed) ES (Completed) NL (Completed) DK (Completed) SE (Completed) HU (Completed) PL (Completed) PT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005585-12 Sponsor Protocol Number: 1 Start Date*: 2007-12-20
    Sponsor Name:Department of Internal Medicine of the University of Munich
    Full Title: Prospektive, offene Studie zur Prüfung der Wirksamkeit der zusätzlichen Gabe des Somatostatinanalogon Octreotid (Sandostatin) bzw. des Dopaminagonisten Cabergolin (Dostinex) bei Patientin mit Akrom...
    Medical condition: acromegaly (= growth hormone hypersecretion mostly caused by a pituitary adenoma)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000265-43 Sponsor Protocol Number: München/CS04 Start Date*: 2018-05-30
    Sponsor Name:Max-Planck-Institut für Psychiatrie
    Full Title: A randomized, placebo-controlled trial comparing the treatment effect of Pegvisomant and the SSRI Escitalopram on depressive acromegalic patients
    Medical condition: Acromegalie with depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 06:50:45 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA